Karyopharm Therapeutics Inc (KPTI) Expected to Post Quarterly Sales of $4.59 Million

Equities research analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to announce sales of $4.59 million for the current quarter, according to Zacks. Four analysts have provided estimates for Karyopharm Therapeutics’ earnings. The highest sales estimate is $15.00 million and the lowest is $50,000.00. Karyopharm Therapeutics posted sales of $70,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 6,457.1%. The business is expected to issue its next quarterly earnings results on Thursday, May 3rd.

On average, analysts expect that Karyopharm Therapeutics will report full year sales of $4.59 million for the current financial year, with estimates ranging from $200,000.00 to $30.00 million. For the next financial year, analysts anticipate that the firm will report sales of $23.50 million per share, with estimates ranging from $6.61 million to $45.41 million. Zacks’ sales averages are an average based on a survey of analysts that cover Karyopharm Therapeutics.

How to Become a New Pot Stock Millionaire

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $2.26 million. Karyopharm Therapeutics had a negative return on equity of 89.62% and a negative net margin of 67,267.47%. The business’s quarterly revenue was up 3163.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.65) EPS.

KPTI has been the subject of several recent research reports. BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine cut Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 6th. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. Royal Bank of Canada restated a “buy” rating and set a $22.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, March 2nd. Finally, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $19.60.

In other news, CEO Michael Kauffman sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $10.09, for a total transaction of $100,900.00. Following the sale, the chief executive officer now owns 522,143 shares in the company, valued at $5,268,422.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christopher Brett Primiano sold 2,500 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $16.03, for a total value of $40,075.00. Following the sale, the executive vice president now owns 4,881 shares in the company, valued at approximately $78,242.43. The disclosure for this sale can be found here. Insiders have sold 69,000 shares of company stock worth $928,625 in the last 90 days. Insiders own 14.71% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Palo Alto Investors LLC boosted its holdings in Karyopharm Therapeutics by 1.3% in the fourth quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock valued at $34,027,000 after acquiring an additional 45,854 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Karyopharm Therapeutics by 6.4% in the fourth quarter. Franklin Resources Inc. now owns 3,337,569 shares of the company’s stock valued at $32,041,000 after acquiring an additional 200,310 shares during the last quarter. State Street Corp boosted its holdings in Karyopharm Therapeutics by 10.1% in the second quarter. State Street Corp now owns 511,920 shares of the company’s stock valued at $4,631,000 after acquiring an additional 47,127 shares during the last quarter. Millennium Management LLC boosted its holdings in Karyopharm Therapeutics by 17.8% in the fourth quarter. Millennium Management LLC now owns 436,836 shares of the company’s stock valued at $4,194,000 after acquiring an additional 65,920 shares during the last quarter. Finally, Iguana Healthcare Management LLC boosted its holdings in Karyopharm Therapeutics by 33.3% in the third quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock valued at $4,392,000 after acquiring an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

Karyopharm Therapeutics stock opened at $13.42 on Monday. The firm has a market cap of $666.34, a price-to-earnings ratio of -4.78 and a beta of 3.62. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $18.00.

TRADEMARK VIOLATION WARNING: This piece was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/04/02/karyopharm-therapeutics-inc-kpti-expected-to-post-quarterly-sales-of-4-59-million.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply